Shandong Weigao Blood (603014.SS) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN CNE100007093
Shandong Weigao Blood financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.60 bn CNY | 3.77 bn CNY |
| Gross profit | 1.52 bn CNY | 1.52 bn CNY |
| Operating income | 556.83 m CNY | 557.04 m CNY |
| EBIT | 546.28 m CNY | 576.57 m CNY |
| Net income | 449.37 m CNY | 482.30 m CNY |
| Diluted EPS – continuing operations | 1.21 CNY | 1.15 CNY |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. The company was founded in 2004 and is based in Weihai, China.
More stocks
- Versigent PLC (VGNT)
- Hugo Boss (BOSS.DE)
- AMERICAN EAGLE OUTFITTERS INC (AEO)
- Dhc Software Co Ltd (002065.SZ)
- NEWMARK GROUP, INC. (NMRK)
- Mobimo Holding AG (MOBN.SW)
- CES Energy Solutions Corp (CEU.TO)
- Sugi Holdings Co Ltd (7649.T)
- Beijing Capital Co Ltd (600008.SS)
- Jilin Aodong Pharmaceutical Group Co Ltd (000623.SZ)
- Denali Therapeutics Inc. (DNLI)
- CAL-MAINE FOODS INC (CALM)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.